ELISA / EIA / RIA Kits · RIA kit · Cat. RK-035-27
INSL3 / RLF (Human) – RIA Kit
Supplied as 125 tubes per unit. Species: Human. Technical values shown are imported catalog fields and should be confirmed against current documentation. Laboratory research use only.
Specifications
| Catalog number | RK-035-27 |
|---|---|
| Product type | ELISA / EIA / RIA Kits · RIA kit |
| Peptide family | Insulin & Insulin-Like Growth Factors (IGF) |
| Species | Human |
| Unit size | 125 tubes |
| Sensitivity | 60.4 pg/ml |
| Specificity | Peptide % Insulin-Like 3 (INSL-3) (Human) 100 Insulin-Like 3 (INSL-3) (Mouse) 0 Insulin (Human) 0 Insulin-Like 4 (INSL-4) (Human) 0 Insulin-Like 5 (INSL-5) (Human) 0 Insulin-Like 6 (INSL-6) (Human) 0 Insulin-Like 7 (INSL-7) (Human) 0 C-peptide (Human) 0 Amylin (Human) 0 Glucagon (Human) 0 GLP-1 (7-37) (Human) 0 GLP-2 (Human) 0 Ghrelin (Human) 0 LH-RH (Human, Porcine, Rat) 0 CGRP (Human) 0 AGRP (83-132) –Amide (Human) 0 |
| Radioactivity | Each kit contains 1.5 µCi of Iodine 125. |
| Inter-Assay CV | <15% |
| Intra-Assay CV | <10% |
| Standard Curve | Contact us for technical specifications on this product. This package conforms to the 49 CFR173.421 for expected radioactive material limited quantity, N.O.S. UN2910. Expression of insulin-like 3 (INSL3) and differential splicing of its receptor in the ovary of rhesus macaques. Hanna CB, Yao S, Patta MC, Jensen JT, Wu X. Reprod Biol Endocrinol. 2010;8:150. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. Gambineri A, Patton L, De iasio R, Palladoro F, Pagotto U, Pasquali R. J Clin Endocrinol Metab. 2007;92(6):2066-73. Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. Page ST, Kalhorn TF, Bremner WJ, Anawalt BD, Matsumoto AM, Amory JK. J Androl. 2007;28(5):734-41. Elevated end-of-treatment serum INSL3 is associated with failure to completely suppress spermatogenesis in men receiving male hormonal contraception. Amory JK, Page ST, Anawalt BD, Coviello AD, Matsumoto AM, Bremner WJ. J Androl. 2007;28(4):548-54. Novel mutations involving the INSL3 gene associated with cryptorchidism. El houate B, Rouba H, Sibai H, et al. J Urol. 2007;177(5):1947-51. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. Page ST, Amory JK, Anawalt BD, et al. J Clin Endocrinol Metab. 2006;91(11):4374-80. Changes in serum insulin-like factor 3 during normal male puberty. Ferlin A, Garolla A, Rigon F, Rasi caldogno L, Lenzi A, Foresta C. J Clin Endocrinol Metab. 2006;91(9):3426-31. Insulin-like factor 3 gene mutations in testicular dysgenesis syndrome: clinical and functional characterization. Ferlin A, Bogatcheva NV, Gianesello L, et al. Mol Hum Reprod. 2006;12(6):401-6. A novel circulating hormone of testis origin in humans. Foresta C, Bettella A, Vinanzi C, et al. J Clin Endocrinol Metab. 2004;89(12):5952-8. GREAT/LGR8 is the only receptor for insulin-like 3 peptide. Bogatcheva NV, Truong A, Feng S, Engel W, Adham IM, Agoulnik AI. Mol Endocrinol. 2003;17(12):2639-46. |
| Standard Range | 10 - 1280 pg/ml |
| Sample Extraction | Recommended |
| Intended use | In vitro laboratory research only — not for human or veterinary use, diagnostic or therapeutic purposes |
Frequently asked
What is INSL3 / RLF (Human) – RIA Kit?
What is the intended use of RK-035-27?
This page reproduces an imported research-catalog record. Verify identity, specifications, documentation and suitability before purchase. The item is offered only for laboratory research and is not represented for human or veterinary use.